---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-002712"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T04:36:09.411963+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Q1 net loss $24.3M ($0.58/sh); 1,244+ patients in Phase 3 simufilam trials

## Summary
- Net loss widened to $24.3M from $17.5M YoY; R&D expense rose to $22.1M on trial costs.
- Cash and equivalents $187.5M, no debt; H1 2023 net cash use guidance reduced to $30-40M from $45-50M.
- Over 1,244 Alzheimer's patients enrolled in Phase 3 program (target ~1,750); enrollment completion expected Q4 2023.
- Phase 2 open-label study showed long-term safety; mild patients had ADAS-Cog improvement vs historical placebo decline.
- Cognition Maintenance Study (randomized withdrawal) results expected Q3 2023; filamin A biological data due Q2 2023.

## SEC filing metadata
- accession: 0001171843-23-002712
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184323002712/0001171843-23-002712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184323002712/f8k_043023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-002712
- JSON: https://secwatch.observer/filing/0001171843-23-002712.json
- Plain text: https://secwatch.observer/filing/0001171843-23-002712.txt

## Key facts
- Earnings Releases
  FILANA THERAPEUTICS, INC. reported three months ended March 31, 2023 results: net income $24.3 million, EPS $0.58 per share.
  - Period: three months ended March 31, 2023
  - Net income: $24.3 million
  - EPS: $0.58 per share
  - Result: reported results
  source text: Net loss was $24.3 million, or $0.58 per share, compared to a net loss of $17.5 million, or $0.44 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000117184323002712/0001171843-23-002712-index.htm
- Earnings Releases
  FILANA THERAPEUTICS, INC. updated its first half 2023 guidance (lowered).
  - Period: first half 2023
  - Guidance: lowered
  - Result: guidance update
  source text: New guidance for net cash use in first half 2023 is expected to be $30 to $40 million, which is revised downward from our previous guidance of $45 to $50 million, due primarily to the timing of certain clinical payment obligations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000117184323002712/0001171843-23-002712-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.